{"groups":[{"description":"Tamoxifen 20mg orally daily for 5 years","id":"FG000","title":"Tamoxifen"},{"description":"Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)","id":"FG001","title":"T+OFS"},{"description":"Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)","id":"FG002","title":"E+OFS"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"146"},{"groupId":"FG001","numSubjects":"70"},{"groupId":"FG002","numSubjects":"135"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"113"},{"groupId":"FG002","numSubjects":"77"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"33"},{"groupId":"FG002","numSubjects":"39"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"57"},{"groupId":"FG002","numSubjects":"49"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1021"},{"groupId":"FG001","numSubjects":"1024"},{"groupId":"FG002","numSubjects":"1021"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"654"},{"groupId":"FG001","numSubjects":"751"},{"groupId":"FG002","numSubjects":"719"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"367"},{"groupId":"FG001","numSubjects":"273"},{"groupId":"FG002","numSubjects":"302"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"3066 patients were randomized between 17Dec03 and 27Jan11 at 426 centers in 25 countries."}